BioSpace News Archive

CANbridge Pharmaceuticals, Inc. announced that it signed the collaboration on a rare disease research agreement with the Peking Union Medical College Hospital, on December 9, 2021.

Illumina, Inc., announced that it is supporting a national precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling in cancer therapy selection testing.

Increasing demand for therapeutics with high purity, rising production of generic drugs, and growing adoption of track etched membrane in food and beverage industry are key factors driving market growth.

NRx Pharmaceuticals (NASDAQ: NRXP) today announced the conclusion of high-level meetings in Hungary that are expected to lead to utilization of ZYESAMI® (aviptadil) in that country and the pivotal clinical trial of the BriLife COVID-19 vaccine (BriLife).

Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1™) who are likely to respond to Denovo’s investigational cancer drug DB102™ for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.

According to Emergen Research, the global AI-based clinical trials solution provider market size was USD 1.24 Billion in 2020 and is expected to reach USD 5.86 Billion in 2028 and register a revenue CAGR of 21.5% during the forecast period, 2021-2028.

IO Biotech today announced the publication of results from its Phase 1/2 MM1636 Melanoma trial in Nature Medicine that can be found HERE.

NEOGEN Corporation (NASDAQ: NEOG) announced today that it has acquired Spokane, Washington -based companion animal genetic testing company Genetic Veterinary Sciences, Inc.

Capsida Biotherapeutics, Inc.,today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in the brain and decreased liver targeting following intravenous (IV) administration in rodents and non-human primates.

Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal investigators, the HS 12-01 database will be locked.